More supply for AtCor
Wednesday, 08 October, 2008
AtCor Medical [ASX: ACG] has signed an agreement to supply its SphygmoCor systems and clinical trial support services to an international pharmaceutical company.
The contract is worth at least US$930,000 [AUD$1.3 million], and has brought to US$3.7 million [AUD$5.2 million] the total value of pharmaceutical trial contracts secured by AtCor in the past 130 days.
SphygmoCor visibly identifies the effects of reflected blood pressure in the central aortic wave. This measure can't be detected with standard blood pressure monitoring.
Fast-aging placentas may contribute to pre-eclampsia
Placentas affected by pre-eclampsia show several signs of accelerated aging, including increased...
BioNTech opens mRNA manufacturing facility at La Trobe
Offering state-subsidised access to researchers and biotech startups, the facility aims to enable...
Personalised melanoma vaccine cuts risk of recurrence
Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...
